PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer.

Combes, Alexander D; Palma, Catalina A; Calopedos, Ross; Wen, Lingfeng; Woo, Henry; Fulham, Michael; Leslie, Scott

Combes, Alexander D; Palma, Catalina A; Calopedos, Ross; Wen, Lingfeng; Woo, Henry; Fulham, Michael; Leslie, Scott.

Afiliação

Combes AD; Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Palma CA; Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Calopedos R; Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Wen L; Department of Molecular Imaging, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Woo H; Faculty of Engineering and Computer Science, University of Sydney, Sydney, NSW 2006, Australia.
Fulham M; Faculty of Medicine, University of Sydney, Sydney, NSW 2006, Australia.
Leslie S; Department of Urology, Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia.

Diagnostics (Basel) ; 12(11)2022 Oct 26.

Article em En | MEDLINE | ID: mdl-36359439

RESUMO

Prostate cancer is the most common cancer and the second leading cause of cancer death in men. The imaging assessment and treatment of prostate cancer has vastly improved over the past decade. The introduction of PSMA PET-CT has improved the detection of loco-regional and metastatic disease. PSMA PET-CT also has a role in the primary diagnosis and staging, in detecting biochemical recurrence after curative treatment and in metastasis-directed therapy. In this paper we review the role of PSMA PET-CT in prostate cancer.

Palavras-chave

PSMA PET; imaging; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google